Bioreactors, 3D rendering. [Love Employee/Getty Images]
South Korea-based LOTTE BIOLOGICS signed a contract manufacturing agreement for antibody therapeutics with Ottimo Pharma, a biopharmaceutical company developing PD1/VEGFR2 dual pathway antibodies (Jankistomig) designed to extend the lives of people living with cancer. LOTTE will manufacture antibody drug substance for Ottimo Pharma’s product at LOTTE’s Syracuse Bio Campus in New York.
“This agreement serves as further validation of our competitiveness as a CDMO in the global antibody therapeutics market,” said James Park, CEO of Park.
“This manufacturing collaboration marks a significant milestone in our commitment to advancing Jankistomig with speed and precision,” added Joseph Shultz, vice president of technical development & manufacturing at Ottimo Pharma. “Partnering with Lotte’s proven biomanufacturing capabilities enhances our operational readiness and supports our rapid path to IND submission and clinical trial initiation.”
LOTTE currently provides CDMO services at its Syracuse Bio Campus, ranging from cell line development to large-scale contract manufacturing of biopharmaceuticals. Additionally, the company aims to begin operation of Plant 1 at its Songdo Bio Campus in South Korea in 2027. Plant 1 will be a large-scale biopharmaceutical manufacturing facility with a production capacity of 120,000 liters, enabling the company to handle major global contracts.
An official at LOTTE says the company has entered into strategic collaborations with global contract development organizations (CDOs) and drug product (DP) companies. Through these partnerships, it offers fully customized CDMO solutions spanning early drug development to commercialization, explained the LOTTE spokesperson.
